Key Highlights
- Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector.
- Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine Solutions and AlliRx.
- Focus areas include hormone optimization, stem cells, and precision health testing.
- Supported by a world-class board with experts in healthcare innovation and longevity medicine.
- Backed by Shore Capital’s resources and operational expertise.
Source: Business Wire
Notable Quotes
- “The longevity marketplace is primed for bold leadership, and I am inspired by the opportunity to help people live a life of wellness while addressing unmet needs in healthcare.” — Jimmy St Louis, CEO at Agentis Longevity
- “We’ve found that American consumers are increasingly motivated to prioritize proactively managing their health, and we are excited to announce another Shore platform investment aligned with the growing theme of consumerization in healthcare.” — Logan Pitts, Vice President at Shore Capital
- “The early-stage growth of the consumer longevity market presents an opportunity to become a national leader by combining cutting-edge services and products with robust clinical practices and education.” — Chris Mioton, Partner at Shore Capital
SoHC's Take
The launch of Agentis Longevity signals a significant milestone in the rapidly expanding field of longevity healthcare. With its focus on innovative treatments like hormone optimization, peptides, and stem cells, Agentis positions itself as a leader in proactive health management. Backed by the operational prowess of Shore Capital Partners and led by the visionary leadership of Jimmy St Louis, this platform is poised to redefine the aging process by emphasizing health span and vitality. Its strategic partnerships and commitment to cutting-edge therapies make it a transformative force in healthcare consumerization.
